This retrospective cohort study reports the effectiveness and safety of mCAPIRI-P regimen on consecutive RAS wild-type (WT) advanced colorectal cancer patients and carcinoembryonic antigen (CEA) kinetics. The gene discussed is CEACAM5; the disease is colorectal cancer.